Sarika Deshmukh, MD
Nephrology · Cedar Park, TXNPI 1093984874
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,541 of the $4,780 with a category attached, or 74.1%. Outset Medical Inc accounts for 76.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,880 and has fallen 90.6% since, to $365 in 2025.
Across 45 payments — averaging $106.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$4K
- Bayer$580
- AstraZeneca$367
- Vifor Pharma, Inc.$67
- Amgen$40
- Akebia Therapeutics Inc$25
- plus $36 from 2 others
What the payments were for
- Consulting fees$3,54174%
- Food & beverage$1,17425%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 2 | $3,666 |
| Bayer | 27 | $580 |
| AstraZeneca(2 entities) | 6 | $367 |
| Vifor Pharma, Inc. | 4 | $67 |
| Amgen(2 entities) | 3 | $40 |
| Akebia Therapeutics Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,780 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 243 | $256,048 |
| JardianceEmpagliflozin | 40 | $49,668 |
| KerendiaFinerenone | 23 | $38,146 |
| TradjentaLinagliptin | 17 | $23,681 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $17,427 |
| InvokanaCanagliflozin | 17 | $13,007 |
| DapagliflozinDapagliflozin Propanediol | 15 | $10,524 |
| Clonidine | 31 | $4,603 |
| Allopurinol | 412 | $3,137 |
| Methenamine Hippurate | 29 | $3,090 |
| Nifedipine ErNifedipine | 88 | $2,980 |
| Febuxostat | 25 | $2,890 |
| Sevelamer Carbonate | 25 | $2,838 |
| Potassium Citrate ErPotassium Citrate | 27 | $1,593 |
| Torsemide | 63 | $1,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $367 | $273,475266 claims |
| BayerKerendia | $580 | $38,14623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Cedar Park
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.